Condition
T Lymphoblastic Leukemia/Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 4 T Lymphoblastic Leukemia/Lymphoma clinical trials that are recruiting, at sites in 2 countries (most in China (3), South Korea (1)). By phase: Phase 1/2 (1), Phase 1 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest T Lymphoblastic Leukemia/Lymphoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| supCD7 CAR-T for relapsed or refractory CD7-positive T-cell leukemia/lymphoma and AML | Phase 1/2 | Tianjin, Tianjin Municipality | Recruiting | Sep 3, 2025 |
| Universal CD7 CAR-T therapy for relapsed or refractory CD7-positive blood cancers | Phase 1 | Tianjin, Tianjin Municipality | Recruiting | Aug 7, 2025 |
| Venetoclax plus decitabine for relapsed or refractory adult T‑cell acute lymphoblastic leukemia/lymphoblastic lymphoma | Phase 2 | Seongnam-si and 2 other locations | Recruiting | Dec 2, 2024 |
| Using CD7 CAR-T cells to treat T-cell lymphoma and leukemia | — | Shenzhen, Guangdong | Recruiting | Nov 17, 2022 |
All recruiting trials (4)
-
supCD7 CAR-T for relapsed or refractory CD7-positive T-cell leukemia/lymphoma and AML
This treatment will try supCD7 CAR‑T cells to see if they help adults whose CD7‑positive T‑cell leukemia/lymphoma or AML has come back or not responded to prior therapy.
-
Universal CD7 CAR-T therapy for relapsed or refractory CD7-positive blood cancers
This trial will test whether universal CD7 CAR-T cells can safely reduce disease in adults whose CD7-positive AML or T-ALL/LBL has relapsed or stopped responding to prior treatments.
-
Venetoclax plus decitabine for relapsed or refractory adult T‑cell acute lymphoblastic leukemia/lymphoblastic lymphoma
This project tests whether seven days of decitabine combined with three weeks of venetoclax can help adults with relapsed or refractory T‑cell acute lymphoblastic leukemia/lymphoblastic lymphoma achieve remission.
-
Using CD7 CAR-T cells to treat T-cell lymphoma and leukemia
This study is testing a new type of treatment using CD7 CAR-T cells to see if it can help adults with T-cell lymphoma and leukemia who haven't had success with other therapies.
Related topics
Quick answers
How many T Lymphoblastic Leukemia/Lymphoma clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (3 trials), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1, Phase 1: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.